Natixis Advisors
AMPH icon

Natixis Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Natixis Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,510
Closed -$225K – 1823
2026
Q1 		$225K Buy
+11,510
New +$282K ﹤0.01% 1677

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Natixis Advisors's AMPH Position: Q2 2026 in Review

Natixis Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2026, closing a stake of 11,510 shares — an estimated $225K sold.

Natixis Advisors first reported a position in AMPH in Q1 2026 and held it in 1 quarter. The position peaked at $225K in Q1 2026. 211 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • Natixis Advisors reported no remaining Amphastar Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Natixis Advisors sold 11,510 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $225K.
  • Natixis Advisors first reported a position in Amphastar Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Natixis Advisors's Amphastar Pharmaceuticals position peaked at $225K in Q1 2026.
  • 211 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.